Last reviewed · How we verify

Mvix — Competitive Intelligence Brief

Mvix (MIRODENAFIL) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Hematology.

marketed cGMP-specific 3',5'-cyclic phosphodiesterase Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Mvix (MIRODENAFIL).

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mvix TARGET MIRODENAFIL marketed cGMP-specific 3',5'-cyclic phosphodiesterase
Stendra AVANAFIL Vivus Llc marketed Phosphodiesterase 5 Inhibitor [EPC] cGMP-specific 3',5'-cyclic phosphodiesterase 2012-01-01
Viagra sildenafil Pfizer Inc. marketed PDE5 inhibitor Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, Multidrug resistance-associated protein 5 1998-03-27
Levitra Levitra Rabin Medical Center marketed Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mvix — Competitive Intelligence Brief. https://druglandscape.com/ci/mirodenafil. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: